Antisense therapy in clinical oncology |
| |
Authors: | Ingo Tamm Mandy Wagner |
| |
Affiliation: | 1. Charité, Campus Virchow, Department for Haematology and Oncology, Forschungshaus, Universit?tsmedizin Berlin, Room 2.0315, Augustenburger Platz 1, 13353, Berlin, Germany
|
| |
Abstract: | Nucleic acid molecules have emerged as versatile tools with promising utility as therapeutics for human diseases. The specificity of hybridization of an antisense oligonucleotide (AS ODN) to the target mRNA makes the AS strategy attractive to selectively modulate the expression of genes involved in the pathogenesis of malignant or non-malignant diseases. One AS drug has been approved for local therapy of cytomegalovirus retinitis, and a number of AS ODN are currently tested in clinical trials including ODN that target bcl-2, survivin, and DNA methyltransferase. The clinical studies indicate that AS ODN are well tolerated and may have therapeutic activity. In this overview, we summarize therapeutic concepts, clinical studies, and new promising molecular targets to treat human cancer with AS ODN. |
| |
Keywords: | Antisense oligonucleotides cancer leukemia targeted therapy bcl-2 protein kinase C α RAF kinase H-RAS protein kinase A DNA methyltransferase |
本文献已被 PubMed SpringerLink 等数据库收录! |
|